CDC Journal And Five Others Rejected Key Paper On COVID Vaccines, Heart Inflammation

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Six medical journals rejected a key paper on COVID-19 vaccines and heart inflammation, a condition the vaccines cause, according to documents reviewed by The Epoch Times.

The U.S. Centers for Disease Control and Prevention (CDC)'s journal, Morbidity and Mortality Weekly Report (MMWR), was one of them.

CDC officials falsely told the paper's authors that the paper did not add anything to a previously published CDC report, which estimated more COVID-19 hospitalizations would be prevented than cases of heart inflammation, or myocarditis, caused.

"I ran this by the MMWR lead editorial staff members; they felt that while the report was interesting, they did not feel that there was anything that was not already relayed," Dr. Jacqueline Gindler, one of the officials, said in an Aug. 10, 2021, email.

The CDC a month earlier in a non-peer-reviewed paper estimated that among males aged 12 to 17, one million second Pfizer doses would cause up to 69 myocarditis cases but prevent some 5,700 COVID-19 cases and 215 COVID-19 hospitalizations.

The new paper clarified the risk-benefit calculus by separating children without serious underlying conditions such as obesity from children with one or more of the problems. It broke down the age group into two parts, 12- to 15 and 16- to 17. And it subtracted incidental hospitalizations, or hospitalizations where people test positive for COVID-19 but are actually being treated for other conditions.

The researchers estimated, using similar methods as the CDC, that one million doses would cause more cardiac adverse events in healthy boys than COVID-19 hospitalizations prevented. Among boys aged 12 to 15 without comorbidities, they calculated up to 6.1 times more adverse events among the vaccinated.

Both the CDC and the new paper utilized reports to the Vaccine Adverse Event Reporting System (VAERS), which the CDC co-manages.

Dr. Tracy Beth Hoeg, one of the paper's co-authors, said that the CDC's position that the paper did not add anything "was laughable."

"What we added was stratification for non high-risk vs high-risk children, which was new," Dr. Hoeg told The Epoch Times in an email. "We also reported a higher rate in 12-17 year olds than CDC had been reporting in males after dose two. Finally we removed incidental COVID-19 hospitalizations, when estimating potential vaccine benefits, which CDC had not been doing up to that point."

Benjamin Hayes, a CDC spokesman who answered a query sent to Dr. Gindler, told The Epoch Times in an email that MMWR had to be "highly selective" due to receiving many submissions during the pandemic.

The New England Journal of Medicine dismissed the paper after having peers review it. One reviewer falsely said that with pre-pandemic myocarditis, adolescents were not known to experience lingering cardiac problems. In fact, deaths and a serious condition called dilated cardiomyopathy have been documented in such patients. Another reviewer said that a major concern was the social consequences of publishing the paper. A third falsely said most post-vaccination cases do not require hospitalization, asserting that offering a risk-benefit analysis based on hospitalization was inappropriate.

"Your paper was evaluated by four external reviewers and a statistical consultant and was discussed among the editors," John Jarcho, the journal's deputy editor, informed the paper's authors. "Although it is interesting, I am sorry to say it was not accepted for publication. This was an editorial decision and reflects an assessment of the merits of your manuscript as compared with the many others we receive."

The statistical reviewer did convey helpful feedback that resulted in adjustments to the paper, authors said.

Dr. Elizabeth Loder, a British Medical Journal, later rejected the paper, offering a similar rationale as the CDC.

"In comparison with the many other papers we have to consider, this one is a lower priority for us. I've reviewed the paper along with another senior editor, and we do not have confidence in the comparison you make in the paper," Dr. Loder said. "The raised risk of myocarditis has been noted before based on this database and the novelty is in the comparison.  That calculation will depend on the prevalence of COVID at the time and it was low in May/June 2021."

A spokesperson for the journal told The Epoch Times in an email: "We are unable to comment in detail about a specific paper, as this is a confidential matter. However, we can say that in general, papers are considered on matters of methodology, potential importance, interest to our broad readership, and on what they add to the established literature. Every paper is thoroughly assessed to ensure that any claims made are supported by robust methods and definitive conclusions before a decision is made."

Dr. Brahmajee Nallamothu, editor-in-chief of Circulation: Cardiovascular Quality and Outcomes, told the authors that he shared their paper with several editors and experts.

"Many of us appreciated you tackling this critical topic, and lending your analytical skills as well as important voices to this debate. However, at the end of the day our concerns were really around the substantial uncertainty of calculating incident estimates using VAERS," he wrote.

Two American Medical Association journals also turned down the paper. One said it was better for a pediatric journal.

"It was really the first time in my life that I was getting this sense the journals were afraid of taking a chance on publishing something," Dr. Hoeg said. "This was particularly frustrating, not because of my own academic career, but because the consequences of them choosing not to publish our findings were adolescents and their families would not be fully informed about the risks of myocarditis from the Pfizer vaccine."

Dr. John Mandrola, a cardiac electrophysiologist based in Kentucky and another co-author, said it was unusual but not unheard of to be rejected by so many journals.

Read more here...